During the past decade, Inje University Seoul Paik Hospital conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 6 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 5 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Inje University Seoul Paik Hospital" #1 sponsor was "Shire" with 5 trials, followed by "Inje University" with 3 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Sewon Cellontech Co., Ltd." with 2 trials sponsored and "Asan Medical Center" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Inje University Seoul Paik Hospital" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Asan Medical Center" with 1 trials as a collaborator, "Chung-Ang University Hosptial, Chung-Ang University College of Medicine" with 1 trials as a collaborator, "Daejeon Eulji Medical Center" with 1 trials as a collaborator and "Eatmapl" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Inje University Seoul Paik Hospital" are "Crohn's Disease" (5 trials), "Ulcerative Colitis" (3 trials), "Hepatitis C Virus" (2 trials), "Osteoarthritis" (2 trials) and "Bradycardia" (1 trials). Many other conditions were trialed in "Inje University Seoul Paik Hospital" in a lesser frequency.

Most popular intervention types in "Inje University Seoul Paik Hospital" are "Drug" (20 trials), "Other" (5 trials), "Device" (3 trials), "Biological" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Ontamalimab" (4 trials), "23-valent polysaccharide pneumococcal vaccine" (1 trials), "24_hours_urine_sodium" (1 trials) and "25 mg Ontamalimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Inje University Seoul Paik Hospital" are 25 trials for "All" genders.

Currently, there are NaN active trials in "Inje University Seoul Paik Hospital". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Inje University Seoul Paik Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Inje University Seoul Paik Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 2 trials that are defined as “Not Applicable".